HER2 Expression in Ovarian Mucinous Carcinomas in Tunisia

  • Missaoui, Nabiha (Research Unit UR14ES17, Cancer Epidemiology and Cytopathology in Tunisian Center, Faculty of Medicine) ;
  • Abdelkarim, Soumaya Ben (Pathology Department, Farhet Hached Hospital) ;
  • Ayachi, Malak (Research Unit UR14ES17, Cancer Epidemiology and Cytopathology in Tunisian Center, Faculty of Medicine) ;
  • Hmissa, Sihem (Research Unit UR14ES17, Cancer Epidemiology and Cytopathology in Tunisian Center, Faculty of Medicine)
  • Published : 2014.10.23


Background: Ovarian mucinous carcinoma has a poor prognosis in advanced stages and a poor response to conventional chemotherapy. An efficient treatment is not yet available. We heere investigated HER2 expression and the potential for trastuzumab therapy in ovarian mucinous tumors. Materials and Methods: Immunohistochemistry was performed in formalin-fixed, paraffin-embedded tissue from 27 ovarian mucinous tumors including 14 carcinomas and 13 borderline tumors diagnosed in the Pathology Department, Farhet Hached Hospital, Sousse, between 1993 and 2013. The HercepTest (DAKO) was used for immunohistochemistry. Results: HER2 expression was observed in only one borderline tumor (7.7%) and in 14.3% of mucinous carcinomas of the ovary. Conclusions: Our results suggest that trastuzumab therapy would be an option for patients with mucinous carcinoma when the tumor has HER2 overexpression.


Ovary;mucinous carcinoma;HER2 expression;immunohistochemistry;trastuzumab therapy


  1. Auersperg N, Wong AS, Choi KC, et al (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev, 22, 255-88
  2. Anglesio MS, Kommoss S, Tolcher MC, et al (2013). Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol, 229, 111-20.
  3. Bookman MA, Darcy KM, Clarke-Pearson D, et al (2003). Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology Group. J Clin Oncol, 21, 283-90.
  4. Chay WY, Chew SH, Ong WS, et al (2013). HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One, 8, 61565.
  5. Cuadros M and Villegas R (2009). Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol, 17, 1-7.
  6. Di Fiore PP, Pierce JH, Kraus MH, et al (1987). erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178-82.
  7. Duman BB, Afsar CU, Gunaldi M, et al (2012). Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients. Asian Pac J Cancer Prev, 13, 4119-23.
  8. Ghaffari SR, Sabokbar T, Dastan J, et al (2011). Her2 amplification status in Iranian breast cancer patients: comparison of immunohistochemistry (IHC). and fluorescence in situ hybridisation (FISH). Asian Pac J Cancer Prev, 12, 1031-4.
  9. Erdogan S, Ergin M, Tuncer I (2003). Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors. Neoplasma, 50, 326-30.
  10. Frederick PJ, Straughn JM Jr, Alvarez RD, et al (2009). Preclinical studies clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol, 113, 384-90
  11. Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, et al (2008). Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Trans Oncol, 10, 367-71.
  12. Hess V, A'Hern R, Nasiri N, et al (2004). Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol, 22, 1040-4.
  13. Goldenberg MM (1999). Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther, 21, 309-18
  14. Gravalos C, Jimeno A (2008). HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 19, 1523-9.
  15. Gurung A, Hung T, Morin J, et al (2013). Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology, 62, 59-70.
  16. Kurman RJ, Seidman JD (2000). Ovarian serous borderline tumors: the citadel defended. Hum Pathol, 31, 1439-42.
  17. Kauraniemi P, Kallioniemi A (2006). Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer, 13, 39-49.
  18. Moatter T, Aban M, Iqbal W, et al (2011). Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients. Asian Pac J Cancer Prev, 12, 3069-73.
  19. Lin WL, Kuo WH, Chen FL, et al (2011). Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer. Ann Surg Oncol, 18, 2388-94.
  20. McAlpine JN, Wiegand KC, Vang R, et al (2009). Overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer, 9, 433.
  21. Missaoui N, Trabelsi A, Parkin DM, el al (2010). Trends in the incidence of cancer in the Sousse region, Tunisia, 1993-2006. Int J Cancer, 127, 2669-77.
  22. Nathanson DR, Nash GM, Chen B, el al (2003). Detection of HER-2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique. J Am Coll Surg, 197, 419-25.
  23. Nicholson RI, Gee JM, Harper ME (2001). EGFR and cancer prognosis. Eur J Cancer, 37, 9-15.
  24. Panagiotou I, Georgiannos SN, Tsiambas E, et al (2012). Impact of HER2 and PTEN simultaneous deregulation in non-small cell lung carcinoma: correlation with biological behavior. Asian Pac J Cancer Prev, 13, 6311-8.
  25. Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 673-84.
  26. Pazhoomand R, Keyhani E, Banan M, et al (2013). Detection of HER2 status in breast cancer: comparison of current methods with MLPA and real-time RT-PCR. Asian Pac J Cancer Prev, 14, 7621-8.
  27. Pectasides D, Farmakis D, Koumarianou A (2005). The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer. Oncology, 68, 64-70.
  28. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-72.
  29. Rubin I, Yarden Y (2001). The basic biology of HER2. Ann Oncol, 12, 3-8.
  30. Sardari Y, Pardis S, Tadbir AA, et al (2012). HER2/neu expression in head and neck squamous cell carcinoma patients is not significantly elevated. Asian Pac J Cancer Prev, 13, 2891-6.
  31. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
  32. Slamon DJ, Godolphin W, Jones LA, et al (1989). Studies of the HER3772/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.
  33. Shak S (1999). Overview of the trastuzumab (Herceptin). anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol, 26, 71-7.
  34. Tai CJ, Pan CK, Chen CS, et al (2013). Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer. Asian Pac J Cancer Prev, 14, 1981-4.
  35. Wang S, Zheng G, Chen L, et al (2011). Effect of HER-2/neu over-expression on prognosis in gastric cancer: a metaanalysis. Asian Pac J Cancer Prev, 12, 1417-23.
  36. Tavassoli FA, Devilee P (2003). Tumours of the breast and female genital organs. IARC, Lyon.
  37. Tuefferd M, Couturier J, Penault-Llorca F, et al (2007). HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One, 2, 1138.
  38. Unal B, Karaveli FS, Pestereli HE, et al (2013). Determination of HER2 gene amplification in breast cancer using dualcolor silver enhanced in situ hybridization (dc-SISH). and comparison with fluorescence ISH (FISH). Asian Pac J Cancer Prev, 14, 6131-4.
  39. Weroha SJ, Oberg AL, Ziegler KL, et al (2011). Phase II trial platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol, 122, 116-20.
  40. Wilson KS, Roberts H, Leek R (2002). Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol, 161, 1171-85.
  41. Wolff AC, Hammond ME, Schwartz JN, et al (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.
  42. Wu Y, Soslow RA, Marshall DS, et al (2004). Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol, 95, 570-5.
  43. Yan B, Choo SN, Mulyadi P, et al (2011). Dual-colour HER2/chromosome 17 chromogenic in situ hybridization enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol, 64, 1097-101.
  44. Ziaian B, Saberi A, Ghayyoumi MA, et al (2014). Association of high LDH and low glucose levels in pleural space with HER2 expression in non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1617-20.

Cited by

  1. pathway is associated with Advanced Ovarian Cancer in Saudi Patients vol.16, pp.14, 2015,
  2. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms vol.36, pp.1, 2017,